These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
152 related articles for article (PubMed ID: 6337600)
21. Endogenous prostacyclin contributes to the efficacy of a thromboxane synthetase inhibitor for preventing coronary artery thrombosis. Aiken JW; Shebuski RJ; Miller OV; Gorman RR J Pharmacol Exp Ther; 1981 Nov; 219(2):299-308. PubMed ID: 6270303 [No Abstract] [Full Text] [Related]
22. A comparison of human pulmonary arterial and venous prostacyclin and thromboxane synthesis--effect of a thromboxane synthase inhibitor. Carter AJ; Bevan JA; Hanley SP; Morgan WE; Turner DR Thromb Haemost; 1984 Apr; 51(2):257-60. PubMed ID: 6377567 [TBL] [Abstract][Full Text] [Related]
23. Thromboxane (Tx) A2 receptor blockade and TxA2 synthase inhibition alone and in combination: comparison of anti-aggregatory efficacy in human platelets. Watts IS; Wharton KA; White BP; Lumley P Br J Pharmacol; 1991 Feb; 102(2):497-505. PubMed ID: 1826620 [TBL] [Abstract][Full Text] [Related]
24. Effect of dazoxiben, a thromboxane synthetase inhibitor on skin-blood flow following cold challenge in patients with Raynaud's phenomenon. Tindall H; Tooke JE; Menys VC; Martin MF; Davies JA Eur J Clin Invest; 1985 Feb; 15(1):20-3. PubMed ID: 3921380 [TBL] [Abstract][Full Text] [Related]
25. SQ 22536, an adenylate-cyclase inhibitor, prevents the antiplatelet effect of dazoxiben, a thromboxane-synthetase inhibitor. Bertelé V; Falanga A; Tomasiak M; Cerletti C; de Gaetano G Thromb Haemost; 1984 Feb; 51(1):125-8. PubMed ID: 6326343 [TBL] [Abstract][Full Text] [Related]
26. A thromboxane synthetase inhibitor reorients endoperoxide metabolism in whole blood towards prostacyclin and prostaglandin E2. Defreyn G; Deckmyn H; Vermylen J Thromb Res; 1982 Jun; 26(6):389-400. PubMed ID: 7051416 [TBL] [Abstract][Full Text] [Related]
27. Acute arterial thrombosis in rabbits: reduced platelet accumulation after treatment with dazoxiben hydrochloride (UK 37,248-01). Randall MJ; Wilding RI Br J Clin Pharmacol; 1983; 15 Suppl 1(Suppl 1):49S-55S. PubMed ID: 6687429 [TBL] [Abstract][Full Text] [Related]
28. Metabolic protection of the reperfused canine endocardium by the thromboxane synthetase inhibitor, dazoxiben. Pieper GM; Farber NE; Gross GJ Prostaglandins Leukot Essent Fatty Acids; 1988 Jul; 33(1):13-22. PubMed ID: 3054935 [TBL] [Abstract][Full Text] [Related]
29. Administration of dazoxiben, a selective thromboxane synthetase inhibitor, in the adult respiratory distress syndrome. Leeman M; Boeynaems JM; Degaute JP; Vincent JL; Kahn RJ Chest; 1985 Jun; 87(6):726-30. PubMed ID: 4039645 [TBL] [Abstract][Full Text] [Related]
30. Dazoxiben examined for platelet inhibitory effect in an artificial circulation. Goldman M; Hall C; Hawker RJ; McCollum CN Br J Clin Pharmacol; 1983; 15 Suppl 1(Suppl 1):61S-65S. PubMed ID: 6681706 [TBL] [Abstract][Full Text] [Related]
31. Prevention of extension of ischaemic damage following acute myocardial ischaemia by dazoxiben, a new thromboxane synthetase inhibitor. Burke SE; Lefer AM; Smith GM; Smith JB Br J Clin Pharmacol; 1983; 15 Suppl 1(Suppl 1):97S-101S. PubMed ID: 6681711 [TBL] [Abstract][Full Text] [Related]
32. Thromboxane generation after thrombin. Protective effect of thromboxane synthetase inhibition on lung fluid balance. Garcia-Szabo RR; Peterson MB; Watkins WD; Bizios R; Kong DL; Malik AB Circ Res; 1983 Aug; 53(2):214-22. PubMed ID: 6684001 [TBL] [Abstract][Full Text] [Related]
33. Pharmacologic modification of blood flow in the rabbit microvasculature with prostacyclin and related drugs. Knight KR; Crabb DJ; Niall M; Angus JA; Martin TJ; O'Brien BM Plast Reconstr Surg; 1985 May; 75(5):692-702. PubMed ID: 3157201 [TBL] [Abstract][Full Text] [Related]
34. The in vivo antiplatelet effects of thromboxane A2 synthase inhibitors are potentiated by simultaneous thromboxane A2/prostaglandin H2 receptor blockade. Golino P; Ambrosio G; Gresele P; Pascucci I; Ragni M; Russolillo E; Leproux GB; Chiariello M J Pharmacol Exp Ther; 1993 Aug; 266(2):511-7. PubMed ID: 8355187 [TBL] [Abstract][Full Text] [Related]
35. Is immunoreactive 6-keto-PGF1 alpha measured in serum after treatment with thromboxane-synthetase inhibitors an index of prostacyclin synthesis? Cerletti C; Chiabrando C; Fanelli R; de Gaetano G Lancet; 1984 Apr; 1(8383):967-8. PubMed ID: 6143907 [No Abstract] [Full Text] [Related]
36. Selective and nonselective inhibition of thromboxane formation. FitzGerald GA; Oates JA Clin Pharmacol Ther; 1984 May; 35(5):633-40. PubMed ID: 6370554 [TBL] [Abstract][Full Text] [Related]
37. Effects of the selective thromboxane synthetase inhibitor, dazoxiben, on cyclic flow variations in stenosed canine coronary arteries. Bush LR; Campbell WB; Tilton GD; Buja LM; Willerson JT Trans Assoc Am Physicians; 1983; 96():103-12. PubMed ID: 6687298 [No Abstract] [Full Text] [Related]
38. Dazoxiben, a thromboxane synthetase inhibitor, in the treatment of Raynaud's syndrome: a double-blind trial. Belch JJ; Cormie J; Newman P; McLaren M; Barbenel J; Capell H; Leiberman P; Forbes CD; Prentice CR Br J Clin Pharmacol; 1983; 15 Suppl 1(Suppl 1):113S-116S. PubMed ID: 6337601 [TBL] [Abstract][Full Text] [Related]